Efficacy and Acceptability of the Luna EMG Rehabilitation Robot on Motor Recovery of the Upper Limb in the Chronic Phase of Stroke

Stroke Clinical Trial

— LUNASTROKE  

Official title:

Efficacy and Acceptability of the Luna EMG Rehabilitation Robot on Motor Recovery of the Upper Limb in the Chronic Phase of Stroke, Experimental Study in Single Cases.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05902910
• Other study ID #: 29BRC21.0393
• Secondary ID: 2022-A00096-37
• Status: Recruiting
• Phase: N/A
• Start date: June 12, 2023
• Est. completion date: April 1, 2024

Study information

• Verified date: June 2023
• Source: University Hospital, Brest
• Contact: Olivier Remy-Neris, PU-PH
• Phone: +33 2 98 22 31 52
• Email: olivier.remyneris[@]chu-brest.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recent work on large cohorts of chronic stroke (>6 months post-stroke) have shown that intensive training of the upper limb in the chronic stroke patients can lead to substantial motor and functional gains that are maintained at 6 months post intervention.

A very prolonged (12 weeks) and very intensive (5 hours daily) training applied to chronic patients after stroke brings a substantial gain both motor and functional which is maintained at 3 months post intervention.

Robotic rehabilitation have been shown to be as effective as any other treatment used in rehabilitation. But the methods of implementation remain widely debated. At that time, most robotic therapies have tried to reproduce functional movement mainly pointing objects.

We want to demonstrate that analytic movements of the elbow and the shoulder performed with the Luna-EMG robot can replace part of usual physiotherapy treatment with at least the same effectiveness on the recovery of fluid movements of the upper limb after a stroke.

Description:

This is a pilot study following a single case experimental design with multiple baselines across subjects (MBD).

People included in the protocol will benefit from 2 hours of daily treatment during 6 to 7.5 weeks. The first 2 weeks will be dedicated to baseline measurement of their upper limb (UL) status with daily treatment for balance and gait control without any treatment of the upper limb. The rest of the time will be dedicated to upper limb treatment exclusively. It will be divided into 2 UL training periods, one of them including a 30mn treatment with the luna EMG robot. The duration of second period will be randomly defined between 2 to 3.5 weeks and the last period will last 2 weeks. The treatment during the first UL treatment period will be randomly allocated to Luna EMG treatment or not. The next period will thus follow the inverse scheme (without if the first contains Luna EMG treatment). The fluidity will be assessed through pointing movements assessed every two days. Evaluation of motor deficiency (Fugl Meyer) and functional status (ARAT score) of the UL will be weekly assessed after the inclusion visit. 3D motion analysis of the UL will also be weekly performed.

All patients will benefit from a regular follow-up and from an organized care protocol. The sessions will be intensive, all subjects will be able to benefit from the new treatment (LUNA EMG). We can expect a direct individual benefit from the proposed intensive treatment, at least for precision of UL movements.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5
• Est. completion date: April 1, 2024
• Est. primary completion date: April 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >= 18 years

• Hemiparesis after a first stroke with more than 1 year time interval

• Functional upper limb: ability to do a pointing task at 90% of the hand-acromion distance (free trunk).

• Spastic hypertonia of the elbow flexors 0-2/4 on the Modified Ashworth scale

• Patient affiliated with social security

• Patient having signed a consent to participate in the research

Exclusion Criteria:

• Inability to sign written consent

• Flexed elbow > 30° during passive mobilization of the upper limb

• EVA>3 in the upper limb at rest or during mobilization

• Complete loss of upper limb proprioception

• Neuro-orthopedic surgery of the upper limb for spasticity: neurotomy, tenotomy, transfer

• Pregnant or breastfeeding woman

Related Conditions & MeSH terms

• Stroke

Intervention

Device:
• LUNA-EMG Robot
During phase B, patients will benefit from functional rehabilitation of their upper limbs and from 30mn of training assisted by the LUMA-EMG robot.

Locations

Country	Name	City	State
France	CHU Brest	Brest

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Brest	EGZOTech

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Fluidity of the upper limb	Repeated evaluation of hand movement by the SPARC index during five pointing tasks at 90% of the length of the upper limb at clavicle height, at comfortable speed.	up to 7.5weeks
Secondary	Pain assessment	Use of Visual Analog Scale (VAS) to evaluate the painful (between 0: no pain to 10: intolerable pain)	up to 7.5weeks
Secondary	Motricity assessment	Use of the Fugl-Meyer index (between 0: no motricity to 66: total member motricity)	up to 7.5weeks
Secondary	Function assessment	ARAT (Action Research Arm Test) measurement to assess specific changes in limb function (from 0 to 57, a low score indicating that the movements cannot be performed, and a high score indicating normal performance)	up to 7.5weeks
Secondary	Duration of movement	Kinematic parameter measured 3 times per week	up to 7.5weeks
Secondary	Straightness of movement	Kinematic parameter measured 3 times per week : the trajectory of the hand during pointing movement at a distance normalised by the length of the upper limb will be assessed in motion capture (12 VICONR cameras). The smoothness of the trajectory will be measured by the SPARC (spectral arc length measure) during forward and backward movement.	up to 7.5weeks
Secondary	Average speed of movement	Kinematic parameter measured 3 times per week : the trajectory of the hand during pointing movement at a distance normalised by the length of the upper limb will be assessed in motion capture (12 VICONR cameras). The spatiotemporal parameters (time, distance, average speed) will be measured between the starting position (in front of the trunc) and the final pointed object during forward and backward movement.	up to 7.5weeks
Secondary	Acceptability of the use of the robot	Score between 0 to 100 (a low score indicate that the robot is not well accepted, and a high score indicate a well acceptability)	up to 7.5weeks
Secondary	Satisfaction of the use of the robot	Score between 0 to 100 (0: not satisfied, 100: very satisfied)	up to 7.5weeks
Secondary	Spasticity	Ashworth scale measured 3 times a week and Nottingham scale measured 1 time at inclusion)	up to 7.5weeks